Thiamine-responsive megaloblastic anemia syndrome: a novel mutation.

Abstract

The thiamine-responsive megaloblastic anemia syndrome (TRMA) is an autosomal recessive disorder characterized by diabetes mellitus, megaloblastic anemia and sensorineural hearing loss due to mutations in SLC 19A2 that encodes a thiamine transporter protein. The disease can manifest at any time between infancy and adolescence, and not all cardinal findings are present initially. The anemia typically improves significantly with pharmacological doses of thiamine. Variable improvement in diabetes is also noted. However, the hearing loss is apparently irreversible, although a delay in the onset of deafness may be possible. We present a 2-year old girl with non-autoimmune diabetes mellitus and anemia in whom we found a novelc.95T>A (leu32X) mutation in the SLC19A2 gene in this study.Our patient with this new mutation did not suffer from hearing loss.

• Authors: S Yilmaz Agladioglu, Z Aycan, V N Bas, H N Peltek Kendirci, A Onder
• Journal: Genetic counseling (Geneva, Switzerland) (Genet Couns) Vol. 23 Issue 2 Pg. 149-56 ( 2012) ISSN: 1015-8146 [Print] Switzerland
• PMID: 22876572 (Publication Type: Case Reports, Journal Article)

Chemical References

• Insulin
• Ketoglutarate Dehydrogenase Complex
• Thiamine

Topics

• Anemia, Megaloblastic (diagnosis, genetics)
• Child, Preschool
• Diabetes Mellitus (diagnosis, drug therapy, genetics)
• Diagnosis, Differential
• Female
• Follow-Up Studies
• Hearing Loss, Sensorineural (diagnosis, genetics)
• Humans
• Insulin (therapeutic use)
• Ketoglutarate Dehydrogenase Complex (deficiency, drug effects, genetics)
• Mutation
• Suppression, Genetic (genetics)
• Thiamine (therapeutic use)
• Thiamine Deficiency (congenital)
• Treatment Outcome